CDMOs in the pharma industry rely heavily on state-of-the-art instrumentation to bring their client’s products from drug development through drug manufacturing to the patient. To better serve their client’s needs as technology and the industry advances, a CDMO must know when to acquire new and emerging technologies, increase their overall instrument capacity, and continually maintain their existing validated instrumentation.
Initial Considerations When Formulating Microparticle-Encapsulated Drugs
In part 1 of a 2 part blog series, we will explore some of the critical factors to consider when beginning work with these types of formulations.